These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 9343116

  • 1. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [Abstract] [Full Text] [Related]

  • 2. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [Abstract] [Full Text] [Related]

  • 3. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
    Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S.
    Neurology; 1998 May; 50(5 Suppl 5):S54-9. PubMed ID: 9591523
    [Abstract] [Full Text] [Related]

  • 4. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
    Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S.
    Neurology; 1997 Oct; 49(4):1066-71. PubMed ID: 9339691
    [Abstract] [Full Text] [Related]

  • 5. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K.
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
    Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, Yoo K.
    Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
    [Abstract] [Full Text] [Related]

  • 8. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S.
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
    Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study Group.
    Mov Disord; 2001 Sep; 16(5):858-66. PubMed ID: 11746615
    [Abstract] [Full Text] [Related]

  • 10. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE.
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [Abstract] [Full Text] [Related]

  • 11. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II).
    Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E.
    Mov Disord; 1997 Nov; 12(6):928-34. PubMed ID: 9399217
    [Abstract] [Full Text] [Related]

  • 12. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
    Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S.
    Neurology; 1997 Sep; 49(3):665-71. PubMed ID: 9305320
    [Abstract] [Full Text] [Related]

  • 13. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH, Spieker S, Clarke CE.
    Cochrane Database Syst Rev; 2004 Oct 18; 2004(4):CD004554. PubMed ID: 15495119
    [Abstract] [Full Text] [Related]

  • 14. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST, Ernst ME.
    Am J Health Syst Pharm; 1999 Nov 01; 56(21):2195-205. PubMed ID: 10565698
    [Abstract] [Full Text] [Related]

  • 15. Highlights of the North American and European experiences.
    Goetz CG.
    Neurology; 1998 May 01; 50(5 Suppl 5):S15-6. PubMed ID: 9591517
    [Abstract] [Full Text] [Related]

  • 16. Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
    Shan DE, Lee SJ, Chao LY, Yeh SI.
    Can J Neurol Sci; 2001 Feb 01; 28(1):70-5. PubMed ID: 11252300
    [Abstract] [Full Text] [Related]

  • 17. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
    Rinne UK, Larsen JP, Siden A, Worm-Petersen J.
    Neurology; 1998 Nov 01; 51(5):1309-14. PubMed ID: 9818851
    [Abstract] [Full Text] [Related]

  • 18. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN.
    Neurology; 1993 Dec 01; 43(12):2685-8. PubMed ID: 8255478
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 01; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM.
    Neurology; 1998 May 01; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.